First-line treatment with Ocrevus (ocrelizumab) preserved walking abilities and hand function in most people with early relapsing-remitting multiple sclerosis (RRMS) over six years, according to data from a Phase 3b clinical trial and its extension study. The findings were presented in a talk by Robert Bermel, MD, of the Cleveland Clinic, at the American Academy […]
The post AAN 2026: Ocrevus preserves walking, hand function in early RRMS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com